Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
Our Qual team has conducted thousands of interviews with patients and medical professionals. We map patient journeys, test and refine diabetes devices in development, assess communication effectiveness and uncover prescribing drivers and barriers.
Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.
